1Lakkis J,La WX,Weir MR.RAAS escape:a real clinical entity that may be important in the progression of cardiovascular and renal disease.Curr Hypertens Rep,2003,5 (5):408-417.
2Sato A,Hayashi K,Naruse M,et al.Effectiveness of aldosterone blockade in patient with diabetic nephropathy.Hypertension,2003,41(1):64-68.
3Struthers AD,MacDonald TM.Review of aldosterone-and angiotensinⅡ-induced target organ damage and prevention.Cardiovascular Research,2004,61 (4):663 -670.
4Ambroisine ML,Milliez P,Nehme J,et al.Aldosterone and anti-aldosterone effects in cardiovasoular diseases and diabetic nephropathy.Diabetes Metab,2004,30(4):311-318.
5Delyani JA.Mineralocorticoid receptor antagonists:the evolution of utility and pharmacology.Kidney Int,2000,57(4):1408-1411.
6Corry DB,Tuck ML.The effect of aldosterone on glucose metabolism.Current Hypertension Reports,2003,5 (2):106-109.
7Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.Report of the expert committee on the diagnosis and classification of diabetes mellitus.Diabetes Care,2000,23 (26 Suppl1):s4-s19.
8Campion J,Maestro B,Molero S,et al.Aldosterone impairs insulin responsiveness in U-937 human promonocytic cells via the dowrregulation of its own receptor.Cell Biochem Funct,2002,20(3):237-245.
